DexCom (DXCM) Director Mark Foletta Sells 4,000 Shares

What Happened Mark G. Foletta, a director of DexCom, sold a total of 4,000 DexCom shares in two open-market transactions. On 2026-07-31 he sold 2,000 shares at $80.00 each for $160,000, and on 2026-08-03 he sold 2,000 shares at $85.32 each for $170,640, for combined proceeds of $330,640. These sales were reported on a Form 4 filed August 4, 2026.

Key Details

• Transaction dates and prices:
  • 2026-07-31: 2,000 shares sold at $80.00 — $160,000
  • 2026-08-03: 2,000 shares sold at $85.32 — $170,640
• Total proceeds: $330,640.
• Sales were open-market dispositions (transaction code S) executed pursuant to a 10b5-1 plan adopted by The Foletta Family Trust on March 13, 2026 (Footnote F1).
• Shares were held by The Foletta Family Trust DTD 1/30/2015; Mark Foletta is a trustee of that trust (Footnote F2).
• The filing was submitted on 2026-08-04 and appears to be timely under Form 4 reporting rules.
• The filing notes unvested restricted stock units granted on 2026-05-28 that will vest on the earlier of the one-year anniversary or DexCom’s 2027 annual meeting (Footnote F3).
• Shares owned after the transactions are not specified in the provided excerpt.

Context These sales were made under a pre-established 10b5-1 plan, which typically authorizes scheduled, systematic dispositions and is intended to insulate the seller from trading on inside information. Sales under such plans are often viewed as routine portfolio-management activity rather than a specific signal about company prospects.